Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (4): 456-463.doi: 10.12092/j.issn.1009-2501.2018.04.016

Previous Articles     Next Articles

Research progress of lncRNA and chemotherapy resistance in colorectal cancer

HU Yang, LI Zhixing, WANG Guo, ZHU Yuanshan   

  1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China; Institute of Clinical Pharmacology of Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, China
  • Received:2018-01-04 Revised:2018-03-08 Online:2018-04-26 Published:2018-04-13

Abstract:

Colorectal cancer (CRC) is a common gastrointestinal tumor with high incidence and mortality rates. Chemotherapy is the basic treatment for colorectal cancer, but chemoresistance is one of the most important causes of therapy failure in CRC, and the mechanism is not yet fully understood. Long noncoding RNA (lncRNA) represents a class of RNA transcripts longer than 200 nucleotides with no protein coding potential which could involve in cancer occurrence and development by the regulation of chromatin remodeling, transcription, and posttranscriptional processing. Recently, emerging evidences indicate that lncRNAs play an important role in the development and maintenance of chemoresistance. Different lncRNAs have been shown to confer chemoresistance in cancer cells by changing multiple drug resistance (MDR) transporters, modulating the cellular apoptosis rate, affecting the epithelial mesenchymal transition (EMT) process, and modulating signaling pathways. In this review, we discuss the mechanism of lncRNAs in drug resistance of colorectal cancer and provide a theoretical evidence for solving the problem of drug resistance in colorectal cancer.

Key words: colorectal cancer, lncRNA, chemotherapy, resistance mechanisms

CLC Number: